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REVIEW
Controversies in bipolar disorder; 
role of second-generation antipsychotic 
for maintenance therapy
Sameer Jauhar1,2*  and Allan H. Young1
Abstract 
In this narrative review, we discuss use of second-generation antipsychotics (SGAs) in maintenance treatment of bipo-
lar disorder. We compare their use to historically more established treatments (particularly lithium, the gold standard). 
To compare we review evidence on efficacy, effectiveness and tolerability across illness poles, possible mechanisms of 
treatment response, guidance given by guideline groups and pragmatic clinical considerations. We then illustrate the 
controversies in maintenance antipsychotic use, with the example of first episode mania and its treatment within first 
episode psychosis services. Finally, we make suggestions for future studies to unpick these differences.
© The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creat iveco mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made.
Introduction
Bipolar disorder (BD), as defined by modern classifica-
tion systems, encompasses episode of mania/hypomania 
and usually depression. Although acute episodes are sig-
nificant, it is the recurrent nature of the illness that has 
implications for longer-term functioning and places it as 
the 4th leading cause of disability adjusted life years in 
people aged 10–24 (Gore et al. 2011).
A careful review on illness course in the pre-medica-
tion and post-medication era suggests recurrence to be 
very much the rule, as opposed to the exception (Good-
win and Jamison 2007). High rates of recurrence are seen 
uniformly throughout illness course, from first episode 
onwards (Gignac et  al. 2015). Because of the high risk 
of episode recurrence, prophylactic treatment is usu-
ally an essential part of treatment. Given that a signifi-
cantly higher proportion of people experience periods 
of depression than (hypo)mania (Judd et al. 2002) treat-
ments should be examined for efficacy for this pole of the 
illness in addition to mania.
Current drugs approved for maintenance therapy 
in bipolar disorder by the United States (US) Food and 
Drugs Administration (FDA) are; lithium, lamotrigine, 
aripiprazole, olanzapine, quetiapine (immediate-release) 
and ziprasidone. Approval has also been given to risperi-
done long acting injection as monotherapy or adjunct, as 
well as aripiprazole long acting injection for monother-
apy in Bipolar 1 disorder (Vieta et al. 2018).
Evidence for the gold standard‑lithium
Lithium has been a cornerstone of maintenance treat-
ment in BD since the 1960s, the first report of pro-
phylactic effects that we are aware of being a report by 
Hartigan in (1963). Initial methodological problems (e.g., 
discontinuation effects causing rebound mania (Sup-
pes et  al. 1991) were addressed by subsequent trials, in 
which lithium was used as comparator to placebo, and in 
latter studies, antipsychotics. Meta-analyses versus pla-
cebo, from 7 trials, indicated benefits of lithium in pre-
venting all mood episodes (RR = 0.66), manic episodes 
(RR = 0.52) and to a lesser extent, depressive episodes 
(RR = 0.78). When compared to anticonvulsants, lithium 
demonstrated superiority in preventing manic episodes 
(RR = 0.66), though not depressive episodes. The long-
est trial length was 2 years, and all but one trial included 
people with Bipolar 1 disorder (Severus et al. 2014). Lith-
ium has also been suggested to have anti-suicide effects 
(Lewitzka et  al. 2015). Effects on cognitive function are 
heterogenous, with small impairments in verbal learn-
ing and memory, though no effects on domains such as 
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executive function or processing speed, with a suggestion 
of worsening in psychomotor speed over time (Wingo 
et al. 2009).
The risks of lithium are clearly delineated and include 
side-effects of treatment (Shine et al. 2015) and rebound 
mania upon discontinuation (Suppes et al. 1991). In the 
former review, the authors examined laboratory data in 
people taking lithium, versus controls finding increased 
risk for stage 3 kidney disease (HR = 1.93), hypothyroid-
ism (HR = 2.31), raised calcium (HR = 1.43). Real-world 
data on lithium discontinuation taken from an epide-
miologically defined area over a 48-year period, of peo-
ple taking lithium, suggested 54% stopped it completely. 
Of the 561 episodes of discontinuation, the majority of 
people stopped due to adverse events (62%), the most 
prevalent being renal disease, diarrhoea and tremor. Psy-
chiatric reasons caused discontinuation in 44% of people, 
the most common being non-adherence and perceived 
lack of effectiveness (Öhlund et al. 2018).
Evidence for second‑generation 
antipsychotics‑how do they compare?
The use of antipsychotics in BD dates back to the 1960s, 
predominantly in the acute phase, compared to placebo 
(Klein and Oaks 1967) and lithium, in acute mania (Prien 
et  al. 1972), as well as functional psychosis (Johnstone 
et al. 1988). The Prien et al. trial found comparable effi-
cacy to lithium in acute mania, and the latter significant 
effects of pimozide, though not lithium, on psychotic 
symptoms, in undifferentiated psychosis. Antipsychotic 
efficacy in acute mania is clear, meta-analytic evidence 
suggesting greater efficacy for haloperidol than lithium 
(SMD 0.19), with heterogeneity between compounds, 
with predominantly dopamine antagonists such as halop-
eridol having greatest efficacy (Cipriani et al. 2011).
The earliest observational study of antipsychotics for 
maintenance treatment appears to be the use of clozapine 
in people attending a service for resistant mood disorders 
(Zarate et  al. 1995). An advantage of the second-gener-
ation antipsychotics (SGAs) was their decreased pro-
pensity to cause movement disorder, in comparison to 
first-generation antipsychotics (FGAs), a 2017 meta-
analysis showing a statistically significant difference in 
tardive dyskinesia between classes (around 20% com-
pared to 30%), with lower prevalence in FGA naïve sub-
jects (around 7%) (Carbon et al. 2017). Other side-effects, 
such as metabolic effects are more prevalent with SGAs 
(see below). A 2017 systematic review and meta-analysis 
of SGAs in maintenance treatment of BD included 15 
RCTs, lasting from 6 months to 2 years, and one obser-
vational study lasting 4  years (Lindström et  al. 2017). 
This examined monotherapy and adjunctive therapy to 
lithium, sodium valproate or lamotrigine. Antipsychotics 
examined included olanzapine (4 trials), quetiapine (4 
trials), aripiprazole (3 trials), risperidone (3 trials) and 
ziprasidone (1 trial). Meta-analyses showed antipsychotic 
monotherapy to be superior to placebo for reducing 
overall relapse risk (olanzapine: RR 0.52 (95% CI 0.38–
0.71), 2 studies; quetiapine: HR 0.37 95% CI 0.31–0.45), 2 
studies; risperidone: RR 0.61 (95% CI 0.47–0.80), 2 stud-
ies), though the quality of studies, using GRADE, was 
very poor. As an adjunct to conventional mood stabilizers 
(lithium/valproate/lamotrigine), when given to people 
who had responded to acute treatment, there was a ben-
eficial effect for aripiprazole (RR 0.65, 95% CI 0.50–0.85; 
2 studies), olanzapine (RR = 0.49 (95% CI 0.27–0.91; one 
study), quetiapine (RR 0.38, 95% CI 0.32–0.46; 2 studies) 
and ziprasidone (RR 0.62, 95% CI 0.40–0.96; 1 study). 
One trial with risperidone long-acting injection (LAI) 
in people with Bipolar 1 disorder and 4 or more episode 
in the prior year, was not statistically significant in the 
meta-analysis for relapse to mania or depression, though 
did show benefit in a 52 week follow-up compared to pla-
cebo as an add-on to treatment as usual, with a 2.3 fold 
decreased risk of relapse to any mood episode (Macfad-
den et  al. 2009). Adjunctive treatment with quetiapine 
was the only drug that reduced both manic (RR 0.39, 95% 
CI 0.30–0.52; 2 studies) and depressive (RR 0.38, 95% CI 
0.29–0.49; 2 studies) episodes. All but one study had an 
enriched design, i.e., patients were taking the drug prior 
to randomization, essentially a form of selection bias. 
Two of the RCTs included people with Bipolar 2 disorder 
(Table 1).
Discontinuation rates as adjunct varied from a hazard 
ratio of 0.66 (ziprasidone) to 0.89 (aripiprazole), with 
weight gain (defined as increase of > 7%) noted when 
meta-analyzing all antipsychotics.
An antipsychotic not examined in this review was lur-
asidone, which has an FDA license as monotherapy and 
adjunctive treatment to lithium and divalproex for acute 
treatment of bipolar depression, and asenapine, which 
has recently been examined in a maintenance trial. Fol-
lowing a 6 week double blind placebo controlled RCT of 
lurasidone monotherapy or adjunctive treatment with 
lithium or divalproex, participants were randomised to 
extended 6-month trial of lurasidone as monotherapy or 
adjunct. Though not primary outcome, treatment‐emer-
gent mania occurred in 1.3% in the monotherapy group, 
and in 3.8% in the adjunctive group. Among extension 
study baseline responders, 10.2% met post hoc crite-
ria for depression relapse during 6 months of treatment 
in the monotherapy group, 10.2% meeting relapse cri-
teria in the adjunctive therapy group. The nature of the 
trial makes it difficult to compare depression and mania 
relapse to other treatments, though the low incidence 
of manic relapse should be noted (Ketter et al. 2016). A 
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Table 1 Polarity, receptor affinities and  side‑effects of  antipsychotics used in  the  maintenance treatment of  bipolar 
disorder
Antipsychotic Polaritya Receptor profile in order of  affinityb Common side  effectsb
Aripiprazole Mania, mixed features D2 partial agonist
5HT2A antagonist
5HT1A partial agonist
5HT7 antagonist
5HT2C partial agonist
α2 antagonist
Akathisia, headache, nausea
Asenapine Mania/mixed features, depression 5HT2c antagonist
5HT2a antagonist
5HT7 antagonist
5HT2b antagonist
5HT6 antagonist
5HT7 α2B antagonist
D3 antagonist
H1 antagonist
α1 antagonist
α2A antagonist
α2C antagonist
D2 antagonist
D1 antagonist
5  HT5a antagonist
5  HT1a partial agonist
H2 antagonist
α1 antagonist
Sedation, EPSEs, postural hypotension
Cariprazine Mania/mixed features D3 partial agonist
D2 partial agonist
5HT2B antagonist
5HT1A partial agonist
5HT2A antagonist
H1 antagonist
5HT7 antagonist
5HT2C antagonist
α 1A antagonist
Akathisia, EPSEs, nausea
Lurasidone Mania/mixed features, depression 5HT7 antagonist
D2 antagonist
5HT2Aantagonist
5HT1Aantagonist
α2 antagonist
EPSEs, sedation
Olanzapine Mania/mixed features,  depressionc H1 antagonist
5HT2A antagonist
5HT2C inverse agonist
D2 antagonist
M1-M5 antagonist
Sedation, weight gain, dyslipidaemia
Quetiapine Mania/mixed features, depression H1 antagonist
α1A antagonist
α2C antagonist
α1B antagonist
α2B antagonist
5HT2A antagonist
D2 antagonist
5HT7 antagonist
Norquetiapine (metabolite of quetia-
pine)
H1 antagonist
5HT2B antagonist
M3 antagonist
M5 antagonist
M1 antagonist
5HT1A partial agonist
5HT2A antagonist
NET inhibitor
α1 antagonist
D2 antagonist (higher doses)
Sedation, weight gain, postural hypotension
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recent 26  week double-blind placebo controlled trial of 
asenapine maintenance therapy in 253 people with bipo-
lar disorder found a statistically significantly longer time 
to recurrence of any mood episode (manic or depres-
sion), HR = 0.16 for manic episode, HR = 0.35 for depres-
sive episode, though not for mixed episodes (though the 
study may have been under-powered, these being post 
hoc analyses) (Szegedi et al. 2018).
To this literature should be added RCTs of long-act-
ing injections (LAIs). A randomized placebo controlled 
52  week trial of aripiprazole depot showed a beneficial 
effect in Bipolar 1 illness, with a hazard ratio of 0.45 in 
recurrence of any mood episode, seen predominantly 
with manic episodes, mirroring evidence for oral ari-
piprazole (Calabrese et  al. 2017). Similar efficacy is also 
seen for risperidone LAI, versus placebo, from two trials, 
of 18 and 24 months’ duration (Quiroz et al. 2010; Vieta 
et  al. 2012), in relapse prevention, with combined risk 
ratio of 0.42 for manic, hypomanic or mixed symptoms, 
though not for depression relapse. A review summaris-
ing three trials of LAI versus oral antipsychotics found 
no difference in relapse rates, though sensitivity analysis 
showed benefit in people with rapid cycling illness (Kishi 
et al. 2016).
The first trial to compare the efficacy of antipsychotic 
monotherapy to lithium for relapse prevention in BD 
examined olanzapine versus lithium for relapse to any 
mood episode. This included open label co-treatment 
for 6–12  weeks, double blind taper over 4  weeks, and 
double-blind monotherapy for 48  weeks. It found no 
inferiority for olanzapine for the primary outcome, hos-
pitalization for any mood episode (Tohen et  al. 2005). 
A 2014 meta-analysis, by Miura et  al., conducted pair-
wise and network meta-analyses examining efficacy and 
tolerability of treatments for the maintenance phase of 
BD. Network meta-analysis accounts for problems seen 
in conventional meta-analyses, where pairwise com-
parisons are made, and enables comparison amongst 
different interventions, given there is a common com-
parator within the network. 33 trials were included in 
the network analysis, examining 17 compounds/combi-
nations. The antipsychotics examined were aripiprazole, 
olanzapine, paliperidone, quetiapine and risperidone 
LAI. It found all interventions were more effective than 
placebo in preventing relapse, apart from aripiprazole, 
carbamazepine, imipramine, and paliperidone. It should 
be noted that more recent studies of aripiprazole were 
not included. Only lithium and quetiapine were more 
effective than placebo for preventing depression relapse. 
The quality of evidence was variable, with the best evi-
dence existing for lithium, in addition to other outcomes 
(e.g., social functioning). This led the authors to conclude 
that lithium should remain first choice therapy for main-
tenance treatment (Miura et  al. 2014). What is striking 
from this meta-analysis of maintenance treatment is the 
degree of similarity of effect to that seen in acute treat-
ment trials-a point made by Taylor, who found a close 
association between best estimates of effect versus pla-
cebo on relapse prevention against response rates for 
acute episodes reported in other network meta-analy-
ses (correlation for manic or mixed episodes, r = – 0.91, 
p = 0.01) and a similar trend for depressive episodes 
(r = – 0.79, p = 0.06) (Taylor 2014). This suggests a true 
effect, as opposed to statistical artefact, and also suggests 
treatments that are effective acutely may be effective 
for prophylaxis. This was recently borne out by a meta-
analysis by the same author, showing lithium had acute 
effects on relapse to mania, within 4 weeks (Taylor 2018).
Given the existing evidence for lamotrigine, licensed in 
the USA and EU for prevention of depression relapse in 
people with Bipolar 1 illness with predominantly depres-
sive episodes (Goodwin et al. 2004), it is worth compar-
ing its effectiveness to antipsychotics-particularly for 
BD after a depressive episode. The Miura network meta-
analysis (above) (Miura et  al. 2014) gave an effect size 
for lamotrigine of 0.69 (95% CI 0.5–0.94) for depressive 
episode, relapse or recurrence. Comparative values for 
antipsychotics were olanzapine 0.8 (95% CI 0.57–1.12), 
quetiapine 0.48 (95% CI 0.34–0.67), risperidone LAI 
1.32 (95% CI 0.84–2.09), and 0.76 (95% CI 0.61–0.93) 
Table 1 (continued)
Antipsychotic Polaritya Receptor profile in order of  affinityb Common side  effectsb
Risperidone Mania 5HT2A inverse agonist
D2 antagonist
5HT7 antagonist
α1 antagonist
5HT2C inverse agonist
H1 antagonist
α2 antagonist
EPSEs, weight gain, elevated prolactin, 
postural hypotension
a Based on RCT and meta-analytic evidence in text, above
b Adapted from Maudsley Psychosis Prescribing Guidelines
c Effective in depression in combination with fluoxetrine
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for lithium. At a pragmatic level, lamotrigine is com-
monly added to other maintenance treatment, includ-
ing antipsychotics, and an important contribution to the 
literature is the CEQUEL trial (Geddes et al. 2016). This 
double-blind placebo-controlled RCT enrolled people 
with a new depressive episode to lamotrigine or placebo, 
finding reduction in depression symptoms (measured by 
the Quick Inventory of Depressive symptomatology-self 
report (QIDS-SR) at 12  weeks and 52  weeks (the latter 
being statistically significant, − 2.69, 95% CI − 4.89 to 
− 0.49]; p = 0.017), with greater improvement in those 
not receiving folic acid.
The only maintenance trial of antipsychotics in post-
first episode mania recruited 61 people with first episode 
manic psychosis whose symptoms had responded to que-
tiapine and lithium and randomized them to quetiapine 
(mean dose 437.5  mg) or lithium (mean level 0.6  mM). 
Using a mixed-model, repeated measures design they 
found lithium superior to quetiapine on clinical meas-
ures (Young Mania Rating Scale (YMRS), Brief Psychiat-
ric Rating Scale (BPRS), clinical global impression), and 
functioning (Berk et al. 2017; Geddes et al. 2016).
In an effort to combine knowledge about drug efficacy 
in maintenance treatment with the clinical picture of 
BD, Popovic et  al. (2012) analyzed trials of greater than 
24 weeks, assigning a polarity index, giving a numerical 
value for prophylactic effects versus depression (< 1) and 
mania (> 1). Examples include 4.38 for aripiprazole and 
0.4 for lamotrigine. This is intuitively appealing, though-
for compounds with equivalent efficacy (e.g. lithium, 
1.39 and quetiapine, 1.14), interpretation may be more 
difficult.
For effectiveness, a recent national (Finnish) register 
study examined rehospitalization of people with bipo-
lar disorder, for a mean of around 7  years. It found ris-
peridone LAI (HR, 0.58 [95% CI 0.34–1.00]), gabapentin 
(HR, 0.58 [95% CI 0.44–0.77]), perphenazine long-acting 
injection (HR, 0.60 [95% CI 0.41–0.88]) and lithium car-
bonate (HR, 0.67 [95% CI 0.60–0.73]) were associated 
with lowest risk of psychiatric rehospitalization. The 
authors acknowledged possible confounders, though 
adjusted for individual variability by using each patient as 
their own control (Lähteenvuo et al. 2018; Popovic et al. 
2012; Berk et al. 2017). The suggested use of LAIs is inter-
esting, given the degree of non-adherence to medication 
seen in BD (20–66%) (Lingam and Scott 2002), though 
the literature from schizophrenia RCTs shows no differ-
ence in relapse rates compared to oral medication (Kishi-
moto et al. 2014).
The superiority of lithium has been echoed in a natu-
ralistic study using a UK primary care database of around 
500 people with BD, where the authors examined use of 
olanzapine, quetiapine, lithium, and sodium valproate 
monotherapy. They examined treatment failure, defined 
as addition of other psychotropic medication or discon-
tinuation, and found longest time to failure for lithium, 
2.05  years (95% CI 1.63–2.51), compared to 0.76  years 
(95% CI 0.64–0.84) for quetiapine, 0.98  years (95% CI 
0.84–1.18) valproate, and 1.13  years olanzapine (95% 
CI 1.00–1.31) (Hayes et al. 2016). The authors were able 
to control for a number of confounding factors, though 
unable to allow for the effects of manic or depressive 
episodes.
Adverse effects of antipsychotics
The main adverse events noted with second genera-
tion antipsychotics include metabolic effects (including 
weight gain, effects on glucose metabolism, cholesterol 
and prolactin), sedation, sexual dysfunction, as well as 
extrapyramidal symptoms (though to a lesser degree than 
FGAs) (Young et  al. 2015). When considering adverse 
events, it should be noted that effects are heterogenous 
between compounds (Leucht et al. 2013), and that inter-
ventions are available to ameliorate side-effects, such 
as weight gain (Young et  al. 2015; Maayan et  al. 2010). 
An analysis using the same UK dataset described above 
found increased rates of hypertension, and 15% weight 
gain, compared to lithium (valproate HR 1.62; 95% CI 
1.31–2.01; p < 0.001, olanzapine HR 1.84; 95% CI 1.47–
2.30; p < 0.001, quetiapine HR 1.67; 95% CI 1.24–2.20; 
p < 0.001).
Methodological issues in appraising the evidence
When appraising RCTs of maintenance treatments in 
BD, it should be acknowledged that follow-up rates are 
low-as low as 10% in some cases, with people excluded 
from trials after experiencing worsening of symptoms, 
such as recurrence of a mood episode. This limits inter-
pretation of results, given that natural history of illness 
may require prolonged treatment with prophylactic med-
ication before beneficial effects may be seen. A related 
issue is the detection of effects on depression episodes-
inclusion criteria for trials is an initial episode of mania 
and given that initial polarity may predict future episode 
polarity, the ability to detect effects on depression may 
be affected, as a result of inadequate statistical power 
(though quetiapine’s effects on this outcome should be 
noted). As above, most trials of antipsychotics adopt an 
enriched design, where participants are stabilized on the 
antipsychotic before randomisation, i.e. preferentially 
choosing responders-though this probably reflects clini-
cal practice. It is worth bearing in mind that those taking 
part in these studies have generally had poor responses 
to lithium or valproate (Lindström et al. 2017). Observa-
tional studies are notoriously difficult to interpret, given 
the effects of confounding factors, and selection bias. It 
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may therefore be helpful to examine aetiological mecha-
nisms and the biology of treatment response.
The mechanism of action of treatment response 
in bipolar disorder
From the above evidence it is clear that response to treat-
ment is heterogenous and that lithium, and to a lesser 
extent, quetiapine, appear most likely to have efficacy in 
preventing relapse to depression. Lithium also appears 
to have anti-suicidal effects. An understanding of the 
pharmacology and neurobiology of treatment response 
enables one to unpick the difference between lithium and 
specific antipsychotics in maintenance therapy.
Various hypotheses exist for lithium response and can 
be grouped into those regulating cell membrane proper-
ties, cell membrane transport and ion distribution, neu-
rotransmitter regulation, and intracellular signalling, 
linked at various levels. An example is its effects on Gly-
cogen Synthase Kinase (GSK) 3β inhibition, with phos-
phorylation of GSKβ through a  Ca2+channel-mediated 
pathway, with inhibition of AKT phosphorylation and 
multiple downstream signalling effects (Alda 2015). Simi-
larly, effects on the dopamine system occur downstream 
of dopamine  D2 receptors (Ashok et al. 2017).
Second-generation antipsychotics (“atypical” antip-
sychotics”) are heterogenous, and this classification is 
based on the pharmacology of clozapine, the first antip-
sychotic found not to cause catalepsy in rodents, and 
clinically significant movement disorder (Gründer et  al. 
2009). They generally have less affinity for the  D2 recep-
tor than first generation antipsychotics, such as halo-
peridol, and more affinity for receptor sites such as the 
 5HT2A receptor (an exception being amisulpride), though 
there is little evidence of an association between this and 
effectiveness. When examining the antipsychotics, it is 
worth considering the Neuroscience-based nomencla-
ture (NbN) which classifies psychotropic medication on 
the basis of their pharmacological profiles (Zohar et  al. 
2014). For those antipsychotics approved for mainte-
nance treatment in BD this is as follows; aripiprazole 
(receptor partial agonist  (D2,  5HT1A), receptor antago-
nist  (5HT2A)), olanzapine (receptor antagonist  D2,  5HT2), 
quetiapine (immediate-release) (receptor antagonist  D2, 
 5HT2), reuptake inhibitor (norepinephrine transporter), 
ziprasidone (receptor antagonist  D2,  5HT2). Given their 
effects in acute bipolar depression it is also worth noting 
the properties of asenapine (receptor antagonist  5HT2, 
 D2, norepinephrine, alpha 2) and lurasidone (receptor 
antagonist  D2,  5HT2).
This nomenclature, with a focus on receptor affinity 
and selectivity give some clue as to the pharmacological 
mode of action necessary for preventing mania- and to 
a lesser extent, depression. In terms of neurobiological 
research, in mania, there is a paucity of in  vivo studies, 
with one Positron Emission Tomography (PET) study 
suggesting no elevation in dopamine synthesis capacity in 
mania, compared to controls (Yatham et al. 2002), though 
an elevation in mania with psychotic symptoms (Jau-
har et  al. 2017). However, taking into account the clini-
cal data, pharmacological studies in healthy volunteers 
and post-mortem studies, it does appear that dopamine 
antagonism has a role in prophylaxis of mania, though 
lithium’s downstream effects on the dopamine signal-
ling is difficult to reconcile with this (Ashok et al. 2017). 
The lack of effects of dopamine antagonists in depression 
suggests a non hyper-dopaminergic mechanism, with 
no clear dopaminergic basis for quetiapine and possi-
bly asenapine’s effects on preventing depression (effects 
on other neurotransmitters such as serotonin (e.g.  5HT7 
receptors being a possibility). Other possible mecha-
nisms include effects on the NMDA system (explaining 
benefits of ketamine in bipolar depression (Bauer et  al. 
2018), and possible hypo-dopaminergia explaining the 
reported positive results of phase III trials of cariprazine 
in bipolar depression (https ://www.aller gan.com/news/
news/thoms on-reute rs/aller gan-annou nces-fda-accep 
tance -of-suppl ement al).
What do guidelines suggest?
Most National guidelines continue to support use of 
lithium as first-line therapy in the maintenance treat-
ment of bipolar disorder [e.g., NICE (https ://www.nice.
org.uk/guida nce/cg185 /chapt er/key-prior ities -for-imple 
menta tion); British Association of Psychopharmacology 
(Goodwin et al. 2016)], with specific antipsychotics rec-
ommended for acute treatment. The use of prophylactic 
agents (grouping together conventional mood stabilizers 
and antipsychotics) is considered on an individual basis, 
based on efficacy and tolerability, with no explicit guid-
ance given by the World Federation of Societies of Bio-
logical Psychiatry (WFSBP) (Grunze et  al. 2013) or the 
Roy al Australian and New Zealand College of Psychia-
trists guidelines (Malhi et  al. 2015). The International 
College of Neuropsychopharmacology (CINP) guidelines 
(Fountoulakis et  al. 2017) have specific suggestions for 
the clinical picture, with quetiapine or olanzapine mono-
therapy suggested if predominantly depressive polarity or 
no predominant polarity, and lithium, aripiprazole, olan-
zapine, paliperidone, quetiapine, risperidone (including 
RLAI) for predominant manic polarity, and olanzapine 
or aripiprazole plus a mood stabilizer for frequent mixed 
episodes and lithium for rapid cycling illness. The Cana-
dian Network for Mood and Anxiety Treatment (CAN-
MAT) and International Society for Bipolar Disorders 
(ISBD) 2018 guidelines for the management of patients 
with bipolar disorder are also more inclusive of other 
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agents, suggesting continuation of treatments used in 
the acute episode. First-line suggestions include lithium, 
quetiapine, divalproex, and lamotrigine monotherapy. 
To these are added asenapine and aripiprazole (oral and 
LAI). They also suggest combination quetiapine with 
lithium/divalproex first-line. An important distinction 
that these guidelines make is for the use of olanzapine as 
second-line therapy, on account of its metabolic effects, 
as well as pointg out use of some SGAs adjunctively for 
short periods of time (Yatham et al. 2018).
The controversial case of treatment of first episode 
mania
A good example of the issues regarding use of antipsy-
chotics in maintenance treatment in BD comes from 
the clinical care of people presenting with first episode 
mania, within first episode psychosis (FEP) services (Jau-
har et  al. 2019). First-line pharmacotherapy will almost 
always be with SGAs, which will be continued for at least 
a year to 18 months, and then either continued or discon-
tinued. Treatment with SGAs in this cohort is associated 
with more prominent metabolic effects and weight gain, 
which will have effects on treatment adherence, which 
can be poor (Whale et al. 2016). This is the biggest fac-
tor predicting relapse (Zipursky et al. 2014), with relapse 
of mania in FEP having more significant consequences in 
terms of hospitalizations than other psychotic illnesses 
such as schizophrenia (Chang et al. 2016). To date, there 
is little data on use of lithium or other mood stabilizers 
in this population over the longer-term, and whether this 
has an effect on treatment adherence or illness course.
Pragmatic clinical questions
Which patients may benefit from antipsychotic 
monotherapy?
Given that lithium is the gold standard, and that antipsy-
chotics have differential effects at various poles of illness, 
when should antipsychotic monotherapy be considered? 
This would pertain to people who are unable to tolerate, 
do not have a good response or do not wish to take lith-
ium. Monotherapy with a LAIs could be considered for 
those who have problems with adherence.
Use of combination antipsychotics
The use of combination antipsychotics is generally dis-
couraged, on account of increased side-effect burden, and 
lack of clear efficacy-even in augmentation of clozapine 
for people with treatment-resistant psychoses. One area 
where antipsychotic combination could be considered is 
when hyperprolactinaemia occurs with an antipsychotic, 
and this cannot be changed, for reasons of efficacy/other 
side-effects. In these cases use of adjunctive aripiprazole 
is justified, in keeping with trial evidence (Raghuthaman 
et al. 2015) and prescribing guidelines (Taylor et al. 2018).
Optimal duration of maintenance antipsychotic treatment
There is little evidence to guide decision-making, regard-
ing length of antipsychotic maintenance treatment. In 
cases of combination therapy (e.g. with lithium) this 
would depend on the initial use of antipsychotic, though 
use as monotherapy would be equivalent to the guidance 
given for lithium, in terms of length of treatment, with 
appropriate monitoring of side-effects.
Conclusions and future directions
Second generation antipsychotics are increasingly used 
for maintenance treatment in bipolar disorder, as mono-
therapy or adjunctive therapy. Although lumped together 
as one class, their pharmacological properties, efficacy 
and tolerability in bipolar disorder are varied. This is par-
ticularly the case for prevention of depressive episodes, 
where their clinical effects appear less pronounced (with 
the exception of quetiapine, and possibly asenapine and 
lurasidone). For people who are intolerant or unable to 
adhere to its use, maintenance treatment with antip-
sychotics seems reasonable, with individualized care 
regarding side effects and their management-and possible 
use of other agents for prevention of depression (e.g. ket-
amine), in conjunction with newer digital technologies, 
for early relapse signs and monitoring (Bauer et al. 2018). 
Future studies examining the neurobiology of treatment 
response in bipolar depression, as well as longer-term tri-
als with various compounds, focusing on treatments act-
ing on differing poles of illness are required.
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